

## **REMARKS**

### **1. The objection to the drawings**

The drawings have been objected to for the quality of Figure 1 as set forth on page 3 of the office action. Applicants concurrently submit a replacement sheet of Figure 1. Applicants respectfully request this objection be withdrawn.

### **2. The objection to the specification**

The specification has been objected to for the phrase “in vivo” at page 152, line 7 as set forth on page 4 of the office action. Applicants have amended the specification to correct the phrase to “in vitro.” Support for the amendments can be found at page 152, lines 4-17 of the specification originally filed. Applicants respectfully request this objection be withdrawn.

### **3. The objection to the claims**

Claims 1, 2, 12, 13, 18, 19, 21 and 22 have been objected to for allegedly reciting non-elected formulae or compounds as well as informalities as set forth on page 4 of the office action. Applicants have amended these claims by deleting the non-elected formulae and correcting the informalities. Applicants respectfully request this objection be withdrawn.

### **4. The rejection under 35 U.S.C. § 112, first paragraph**

Claims 1, 7, 8, 10-12, 18 and 21 have been rejected under 35 U.S.C. §112, first paragraph, because the specification allegedly fails to enable the full scope of the claimed invention. Claims 2, 13, 19 and 22 have been rejected under 35 U.S.C. §112, first paragraph, because the specification allegedly fails to enable the full scope of the claimed invention.

Applicants have amended independent claims 1 and 2 to recite a method of inhibiting hyperproliferative cell growth and activity of p56<sup>lck</sup> molecule respectively to better capture the envisioned commercial embodiments and to remove the non-elected species. Support for the amendments can be found in the original claims and original specification, for example, at pages 149-152. Applicants respectfully submit that the specification fully enables the full scope of the

## 5. Conclusion

Applicants respectfully request reconsideration and withdrawal of the objections and enablement rejection. Should the Examiner find that an interview would be helpful to further prosecution of this application, he is invited to telephone the undersigned at his convenience.

By: /Todd B. Buck/  
Todd B. Buck, Ph.D.  
Registration No. 48,574  
Tel. No.: (202) 739-5698  
Fax No.: (202) 739-3001